LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
16 October 2023 – LimmaTech Biologics AG announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea. Later-stage clinical development efforts will focus on the company’s Shigella vaccine program, which LimmaTech developed as part of a joint collaboration with GSK and recently exclusively in-licensed. The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023.
Walder Wyss advised the investors Adjuvant Capital, AXA IM Alts and the Novo Holdings REPAIR Impact Fund in the transaction. The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Senior Associate, Corporate/M&A and Venture Capital), Lucas Maurer (Associate, Corporate/M&A and Venture Capital) as well as Simon Olstein (Associate, Corporate/M&A and Venture Capital).